Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3.
doi: 10.1097/INF.0000000000004922. Online ahead of print.

Both Corticosteroids and Intravenous Immunoglobulin Protect From Aneurysms in Children With Multisystem Inflammatory Syndrome (MIS-C): A Multicenter Ambispective Study

Cinta Moraleda  1   2 , Kamila Ludwikowska  3 , Irati Gastesi  2 , Magdalena Okarska-Napierała  4 , Cristina Epalza  1   2 , Fernando Paredes-Carmona  5 , Andrea Ramírez Varela  6 , Natalia Kulboka  4 , Miron Kursa  7   8 , Victoria Fumadó  9 , Abel Martínez-Mejías  10 , Sara Domínguez-Rodríguez  2   11 , María Lucía Mesa-Rubio  6 , Ernest Kuchar  4 , Carlos Grasa  12   13   14 , Antoni Soriano-Arandes  15 , Leszek Szenborn  3 , María Isabel Iglesias-Bouzas  16 , Ana Roche-Gómez  1 , Alfredo Tagarro  2   17   18 ; International Working Group on Aneurysms in MIS-C.
Collaborators, Affiliations

Both Corticosteroids and Intravenous Immunoglobulin Protect From Aneurysms in Children With Multisystem Inflammatory Syndrome (MIS-C): A Multicenter Ambispective Study

Cinta Moraleda et al. Pediatr Infect Dis J. .

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a post-COVID-19 condition resembling Kawasaki disease, including developing coronary aneurysms. Optimal treatment remains uncertain. This study aims to identify effective therapies for preventing aneurysms in MIS-C and associated risk factors.

Methods: This multicenter, ambispective study included hospitalized patients 0-18 years old with MIS-C between March 2020 and June 2023 from cohorts in Poland, Spain, Catalonia and Colombia. Logistic regression analyzed aneurysm risk factors. Treatment efficacy was assessed using Kaplan-Meier and Cox proportional hazards models, with post hoc Tukey's tests for pairwise comparisons.

Results: Among 853 patients, 33 (4%) developed aneurysms, with a median age of 5.86 years (interquartile range, 3.00-11.7). All immunomodulatory treatments reduced aneurysm risk compared with no immunomodulatory treatment: corticosteroids + intravenous immunoglobulin (IVIG) [odds ratio (OR): 0.29; 95% confident interval (CI): 0.13-0.68], corticosteroids alone (OR: 0.27; 95% CI: 0.04-1.02) and IVIG alone (OR: 0.49; 95% CI: 0.18-1.28). Kaplan-Meier analysis showed a significantly lower 7-day aneurysm-free probability without immunomodulatory treatment (92%; 95% CI: 87%-96%, P = 0.011). Hazard ratios indicated a reduction in aneurysm risk with corticosteroids+IVIG [hazard ratio (HR) = 0.29; 95% CI: 0.13-0.65], corticosteroids alone (HR = 0.25; 95% CI: 0.06-1.13) and IVIG alone (HR = 0.49; 95% CI: 0.19-1.25), but no significant differences were observed between these treatments. No additional aneurysm risk factors were identified.

Conclusions: Corticosteroids, IVIG and their combination appear to be protective against aneurysms in children with MIS-C compared with no immunomodulatory treatment. Although the 3 therapies showed no significant differences when compared with each other, only the combination significantly reduced the risk. Corticosteroids may still be a useful option when IVIG is limited.

Keywords: SARS-CoV-2; aneurysms; corticosteroids; intravenous immunoglobulin; multisystem inflammatory syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al.; EPICO-AEP Working Group. Multi-inflammatory syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis. 2021;72:e397–e401.
    1. Yeung RS, Ferguson PJ. Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum? J Clin Invest. 2020;130:5681–5684.
    1. Grande Gutierrez N, Mathew M, McCrindle BW, et al. Hemodynamic variables in aneurysms are associated with thrombotic risk in children with Kawasaki disease. Int J Cardiol. 2019;281:15–21.
    1. Henderson LA, Canna SW, Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022;74:e1–e20.
    1. Ouldali N, Toubiana J, Antona D, et al.; French Covid-19 Paediatric Inflammation Consortium. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–864.

LinkOut - more resources